Icrucumab

Source: Wikipedia, the free encyclopedia.
Icrucumab
VEGFR-1
Clinical data
Other namesIMC-18F1
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6514H10024N1756O2032S42
Molar mass146796.63 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.[1][2]

Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.[3]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
  2. S2CID 34756277
    .
  3. ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov
Retrieved from "https://en.wikipedia.org/w/index.php?title=Icrucumab&oldid=1147938809"